Boehringer Ingelheim Initiates Long-term Study of Spesolimab for Hidradenitis Suppurativa
Boehringer Ingelheim is conducting a long-term study to evaluate the tolerance and efficacy of spesolimab in patients with hidradenitis suppurativa.
Therapeutic Area
Therapeutic area intelligence for Hidradenitis Suppurativa with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.